Related references
Note: Only part of the references are listed.Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder
Malin Fromme et al.
JOURNAL OF HEPATOLOGY (2022)
Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease
Nan He et al.
JCI INSIGHT (2022)
Liver-directed SERPINA1 gene therapy attenuates progression of spontaneous and tobacco smoke-induced emphysema in α1-antitrypsin null mice
Marina Zieger et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)
Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency
Pavel Strnad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Current Clinical Applications of In Vivo Gene Therapy with AAVs
Jerry R. Mendell et al.
MOLECULAR THERAPY (2021)
Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells
Motahareh Arjomandnejad et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice
Pengpeng Liu et al.
NATURE COMMUNICATIONS (2021)
T Cell-Mediated Immune Responses to AAV and AAV Vectors
Hildegund C. J. Ertl
FRONTIERS IN IMMUNOLOGY (2021)
Alpha1-antitrypsin deficiency: New therapies on the horizon
Katharina Remih et al.
CURRENT OPINION IN PHARMACOLOGY (2021)
Lung and liver transplantation in patients with alpha-1 antitrypsin deficiency
Martin R. Zamora et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2021)
Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what's down the road?
Franck F. Rahaghi
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2021)
Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans
Gwladys Gernoux et al.
MOLECULAR THERAPY (2020)
α1-Antitrypsin deficiency and chronic respiratory disorders
Mario Cazzola et al.
EUROPEAN RESPIRATORY REVIEW (2020)
Alpha1-Antitrypsin Deficiency
Pavel Strnad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Advances in Alpha-1 Antitrypsin Gene Therapy
Reka Lorincz et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2020)
Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma
Adriana L. da Silva et al.
SCIENCE ADVANCES (2020)
Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
Robert A. Sandhaus et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2020)
Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives
Mark Quinn et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
Liver disease in adults with severe alpha-1-antitrypsin deficiency
Hanan A. Tanash et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Adeno-associated virus vector as a platform for gene therapy delivery
Dan Wang et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy A Pilot Clinical Trial
Michael A. Campos et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Bridging from Intramuscular to Limb Perfusion Delivery of rAAV: Optimization in a Non-human Primate
Alisha M. Gruntman et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency
Anita Pye et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease
S. A. Townsend et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice
Shen Shen et al.
HUMAN GENE THERAPY (2018)
In vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency
Chun-Qing Song et al.
HUMAN GENE THERAPY (2018)
An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy
Gregg A. Duncan et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates α1-antitrypsin Deficiency Phenotype
Mikael Bjursell et al.
EBIOMEDICINE (2018)
Alpha-1 Antitrypsin Deficiency as a Candidate for Gene Editing
Terence R. Flotte
HUMAN GENE THERAPY (2018)
Update on α1-antitrypsin deficiency
Ilaria Ferrarotti et al.
BREATHE (2018)
5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency
Christian Mueller et al.
MOLECULAR THERAPY (2017)
Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency
Florie Borel et al.
MOLECULAR THERAPY (2017)
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)
Noel G. McElvaney et al.
LANCET RESPIRATORY MEDICINE (2017)
Lentiviral expression system for the purification of secreted proteins from human cell cultures
Alexander Falkenhagen et al.
BMC BIOTECHNOLOGY (2016)
Tyrosine Mutation in AAV9 Capsid Improves Gene Transfer to the Mouse Lung
Sabrina V. Martini et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
Vector serotype screening for use in ovine perinatal lung gene therapy
Lauren E. McClain et al.
JOURNAL OF PEDIATRIC SURGERY (2016)
Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease
Maria J. Chiuchiolo et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2016)
Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy
Joanna Wozniak et al.
HUMAN GENE THERAPY (2015)
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial
Kenneth R. Chapman et al.
LANCET (2015)
Progress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin Deficiency
Alisha M. Gruntman et al.
HUMAN GENE THERAPY METHODS (2015)
Emergence of a Stage-Dependent Human Liver Disease Signature with Directed Differentiation of Alpha-1 Antitrypsin-Deficient iPS Cells
Andrew A. Wilson et al.
STEM CELL REPORTS (2015)
Single Tyrosine Mutation in AAV8 Vector Capsid Enhances Gene Lung Delivery and Does Not Alter Lung Morphofunction in Mice
Sabrina V. Martini et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2014)
DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma
Adriana L. da Silva et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Intramuscular Injection of AAV8 in Mice and Macaques Is Associated with Substantial Hepatic Targeting and Transgene Expression
Jenny A. Greig et al.
PLOS ONE (2014)
Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression
Christian Mueller et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Sustained miRNA-mediated Knockdown of Mutant AAT With Simultaneous Augmentation of Wild-type AAT Has Minimal Effect on Global Liver miRNA Profiles
Christian Mueller et al.
MOLECULAR THERAPY (2012)
Implications of the innate immune response to adenovirus and adenoviral vectors
Seth M. Gregory et al.
FUTURE VIROLOGY (2011)
Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing α1-Antitrypsin: Interim Results
Terence R. Flotte et al.
HUMAN GENE THERAPY (2011)
Gene therapy for alpha-1 antitrypsin deficiency
Terence R. Flotte et al.
HUMAN MOLECULAR GENETICS (2011)
Spontaneous hepatic repopulation in transgenic mice expressing mutant human α1-antitrypsin by wild-type donor hepatocytes
Jianqiang Ding et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells
Kosuke Yusa et al.
NATURE (2011)
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells
Federico Mingozzi et al.
BLOOD (2009)
Recombinant AAV Serotype and Capsid Mutant Comparison for Pulmonary Gene Transfer of alpha-1-Antitrypsin Using Invasive and Noninvasive Delivery
Rejean Liqun Wang et al.
MOLECULAR THERAPY (2009)
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
Mark L. Brantly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Does the use of recombinant AAV5 in pulmonary gene therapy lead to lung damage?
S. V. Martini et al.
RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY (2009)
Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 α1-antitrypsin (AAT) vector in AAT-deficient adults
Mark L. Brantly et al.
HUMAN GENE THERAPY (2006)
High levels of persistent expression of (A-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses
BP De et al.
MOLECULAR THERAPY (2006)
PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization
GK Lee et al.
BIOTECHNOLOGY AND BIOENGINEERING (2005)
Intrapleural administration of a serotype 5 adeno-associated virus coding, for α1-antitrypsin mediates persistent, high lung and serum levels of α1-antitrypsin
B De et al.
MOLECULAR THERAPY (2004)
Production and recovery of recombinant protease inhibitor α1-antitrypsin
IM Tamer et al.
ENZYME AND MICROBIAL TECHNOLOGY (2001)
Transfection of nasal mucosa with a normal α1-antitrypsin gene in α1-antitrypsin-deficient subjects:: Comparison with protein therapy
KL Brigham et al.
HUMAN GENE THERAPY (2000)
Share Paper
